Novo Holdings co-leads Swiss funding round

HBM Partners and Novo Holdings have joined forces to co-lead a CHF 100m investment round in biotech firm Numab which is developing a cancer treatment that will compete with one of Genmab's projects.

Nanna Lüneborg Partner at Novo Ventures. | Photo: Novo Ventures

Swiss biotech company Numab has received a capital injection for the further development of its main candidate for treating a series of cancer diseases.

Numab has secured CHF 100m (USD 111m) in a series C capital raising round co-led by Novo Holdings and HBM Partners.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs